www.geneplus.org.cn-05-Figure 2. Timing and Duration of Tyrosine Kinase Inhibitor (TKI) Treatment, Breaks, and Retreatment12 patients eventually experienced disease progression while receiving TKI retreatment and were administered next-line treatment by their physicians. The median TTNT from the initia...
Swimmer plots showing the timing of consolidation CPI, progression based on RECIST 1.1 evaluation of imaging, and the results of ctDNA analyses for patients with (A) and without progression (B). One patient (B081-1082) ...
et al. Clonal status of actionable driver events and the timing of mutational processes in cancer ...
那么，有没有一种方法，让我们在复发病灶处于襁褓状态就发现它们，这样可以更好地介入干预，从而提高治疗...
During this conversation, Lee delves into the growing role of MRD testing and how results guide transplant timing and maintenance therapy deintensification. He also highlights the balance between patient preferences and long-term outcomes with advanced therapies like CAR T-cell and bispecific antibodies...
Timing of MRD Calculations to Be Changed.Reports on the determinations required with respect to a person's distributions under the U.S. Internal Revenue Service's proposed regulations on minimum required distributions. Difficulties that could arise from the requirement....
Eunice Wang, MD: But I think the timing is unsure because if you have somebody who’s MRD-positive who has persistent disease, even though they’re morphologically or clinically in a remission, we don’t have a good agent. So that might be the person we’re in the absence of knowing ...
the timing for completion of ALPHA3 enrollment or cema-cel BLA submission; the incidence of LBCL including the extent to which patients will relapse and require subsequent treatment; the potential for our product candidates to be approved; the potential benefits of the ALPHA3 trial and of...
CancerTiming of MRD-testingMRD-testing assayMRD cut-off threshold (%)Cases with positive MRD-testsCases with negative MRD-testsOdds ratio for CIRSensitivitySpecificityRef. NCIRNCIR BCR::ABL1-positive ALL 3 months after CR MPFC 0.1 5 ≈55% at 4 years 46 ≈25% at 4 years 3.67 0.19 0.94 ...
McGranahan N, Favero F, De Bruin E C, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution[J]. Science translational medicine, 2015, 7(283): 283ra54-283ra54. 不想下载原文的可公众号“玩转ATGC”后台发送“Signatera”获取两篇文献原文。